NEWS

Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting
Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting 04/19/2023
Aer Therapeutics Closes $36 Million Series A to Advance Development of AER-01, an Innovative Mucolytic for the Treatment of Lung Diseases
Aer Therapeutics Closes $36 Million Series A to Advance Development of AER-01, an Innovative Mucolytic for the Treatment of Lung Diseases 04/14/2023
The First FDA-Approved Video Game Was Developed in San Francisco
The First FDA-Approved Video Game Was Developed in San Francisco 04/10/2023
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Therapies for Autoimmune Diseases
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Therapies for Autoimmune Diseases 04/03/2023
Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai’s Novel RNA-based Liquid Biopsy Platform in Breast Cancer
Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai’s Novel RNA-based Liquid Biopsy Platform in Breast Cancer 03/30/2023
UCSF Speakers Reach Record Numbers at 2023 Precision Medicine World Conference
UCSF Speakers Reach Record Numbers at 2023 Precision Medicine World Conference 03/29/2023
ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform
ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform 03/29/2023
EpiBiologics Launches with $50 million to Advance Next-Generation Protein Degradation Platform
EpiBiologics Launches with $50 million to Advance Next-Generation Protein Degradation Platform 03/23/2023
MindRhythm's EPISODE-PS Initial Trial Results are Published
MindRhythm's EPISODE-PS Initial Trial Results are Published 03/16/2023
Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal
Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal 03/06/2023
Nested Therapeutics Announces Nomination of First Development Candidate, a Potential First-in-Class Inhibitor of the RAS/MAPK Pathway
Nested Therapeutics Announces Nomination of First Development Candidate, a Potential First-in-Class Inhibitor of the RAS/MAPK Pathway 03/02/2023
Chroma Medicine Secures $135M in Series B Financing
Chroma Medicine Secures $135M in Series B Financing 03/01/2023
MindRhythm Initiates Pivotal Portion of Prehospital Stroke Trial
MindRhythm Initiates Pivotal Portion of Prehospital Stroke Trial 02/15/2023
The University of California and Foundery Sign Master Agreement to Translate Novel Discoveries into Transformational Immunotherapies
The University of California and Foundery Sign Master Agreement to Translate Novel Discoveries into Transformational Immunotherapies 02/09/2023
Long-term functional regeneration of radiation-damaged salivary glands through delivery of a neurogenic hydrogel
Long-term functional regeneration of radiation-damaged salivary glands through delivery of a neurogenic hydrogel 02/02/2023